ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

OZEMPIC
Diabetes
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

OZEMPIC Rx

Generic Name and Formulations:
Semaglutide 2mg/1.5mL (1.34mg/mL); per pen injector; soln for SC inj.

Company:
Novo Nordisk

Therapeutic Use:

RECENT UPDATES

Monograph added.

Indications for OZEMPIC:

As adjunct to diet and exercise, to improve glycemic control in type 2 diabetes mellitus (T2DM).

Limitations Of use:

Not recommended as first-line therapy for patients inadequately controlled on diet and exercise. Not studied with a history of pancreatitis. Not a substitute for insulin. Not for treating type 1 diabetes or diabetic ketoacidosis.

Adult:

Give by SC inj in abdomen, thigh, or upper arm; rotate inj sites. Initially 0.25mg once weekly for 4 weeks, then 0.5mg once weekly for at least 4 weeks; if additional control needed, may increase to 1mg once weekly (max).

Children:

<18yrs: not established.

Contraindications:

History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.

Warnings/Precautions:

Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of diabetic retinopathy; monitor for progression. Do not reuse or share pens or needles between patients. Monitor renal function when initiating or escalating dose. History of anaphylaxis or angioedema with another GLP-1 agonist. Pregnancy. Females of reproductive potential: discontinue ≥2 months prior to planned pregnancy. Nursing mothers.

Interactions:

Concomitant insulin; administer as separate injections not adjacent to each other. Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need lower dose of these. May affect absorption of concomitant oral drugs (delayed gastric emptying); caution.

Pharmacological Class:

Glucagon-like peptide-1 (GLP-1) receptor agonist.

Adverse Reactions:

Nausea, vomiting, diarrhea, abdominal pain, constipation; rare: pancreatitis, hypersensitivity reactions (discontinue if occur).

Generic Availability:

NO

How Supplied:

Single-patient-use pre-filled pen (0.25mg or 0.5mg per inj)—1; (1mg per inj)—2

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs